Recent Updates — CMMB

On September 23, 2026, Chemomab Therapeutics Ltd., Scipher Medicine Corporation, and related entities executed Amendment No. 1 to their Agreement and Plan of Merger. The amendment introduces a formula-based exchange ratio for the Domestication Merger to ensure the combined entity has exactly 10,000,000 shares outstanding immediately following closing. This technical adjustment does not alter the transaction's economic value or relative ownership allocation between Chemomab and Scipher. The merger is expected to close in the fourth quarter of 2026, resulting in Chemomab redomiciling to the U.S., listing on Nasdaq under ticker "SCIP," and becoming a wholly owned subsidiary of the combined company led by CEO Reginald Seeto. Chemomab Therapeutics Ltd. operates in the biotechnology industry, focusing on developing novel antibody-based therapies for cancer and inflammatory diseases.

Chemomab Therapeutics reported a net loss of $3.9 million for the six months ended June 30, 2026, with cash and short-term deposits totaling $6.7 million. The company disclosed a subsequent event on July 7, 2026: a definitive merger agreement with Scipher Medicine Corporation to form a combined U.S.-based entity trading as SCIP on Nasdaq. Under the all-stock transaction, Chemomab shareholders will own approximately 32% of the combined company, while Scipher shareholders will hold 68%. The deal includes a concurrent private placement (PIPE) for at least $30 million and contingent value rights for Chemomab holders tied to nebokitug milestones. The combined entity plans to advance nebokitug into a Phase 2 precision medicine trial in rheumatoid arthritis, leveraging Scipher’s diagnostic platform. Chemomab Therapeutics operates as a clinical-stage biotechnology company focused on discovering and developing therapeutics for inflammatory and fibrotic conditions.

Chemomab Therapeutics Ltd. entered into a merger agreement on July 7, 2026, to redomicile into the U.S. and merge with Scipher Medicine Corporation, with Scipher becoming a wholly owned subsidiary. The transaction includes a concurrent PIPE investment of at least $30 million, reflecting a combined company valuation of $150 million, and Chemomab shareholders will receive contingent value rights (CVRs) for the nebokitug asset. The merger is expected to be completed in the fourth calendar quarter of 2026. Chemomab Therapeutics Ltd. is a biotechnology company focused on developing therapeutic solutions.